Bayer Weighs Structural Changes But Rules Out Three-Way Split

Updated Nov. 8, 2023 5:07 am ET Bayer Chief Executive Bill Anderson said he is looking at options to overhaul the company’s structure and remove multiple layers of management in a move that will result in significant job cuts, but ruled out splitting the group into three businesses. Anderson, who took the helm of the … Read more

Health Care Roundup: Market Talk

Updated Nov. 7, 2023 12:32 pm ET The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1144 ET – Hims & Hers Health’s weight management business will be launched in time for the January rush when people often set new year’s … Read more

How Old Am I, Really? These Tests Measured My Biological Age

How old am I, really? I spat in a tube, swabbed the inside of my cheek and pricked my finger to find out.  I mailed my samples to three companies that promised to tell me my “biological age” based on chemical modifications of my DNA. The results, the companies said, would be based not on … Read more

Johnson & Johnson Considers Ditching Texas Two-Step for Third Talc Bankruptcy

Oct. 20, 2023 5:22 pm ET|WSJ Pro Johnson & Johnson is exploring a new bankruptcy filing for its talc-related liabilities using a different corporate structure than the Texas Two-Step filings that failed twice before to resolve those mass claims in chapter 11, according to people familiar with the company’s plans. The healthcare-products company said on a … Read more

Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion

Oct. 19, 2023 10:06 pm ET Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22 billion. Merck and Daiichi Sankyo will develop and commercialize three antibody drug conjugate candidates—patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan—worldwide. Daiichi Sankyo will retain exclusive rights in Japan. … Read more

Health Care Roundup: Market Talk

Find insight on Bristol Myers, IHH Healthcare and more in the latest Market Talks covering the Health Care sector. Source link

Your Medical Devices Are Getting Smarter. Can the FDA Keep Up?

Use of AI means devices and apps can learn and change over time, creating challenges for regulators who need to make sure they’re safe Source link

GSK Partners With Zhifei on Vaccines in China

GSK said it has an exclusive agreement with Zhifei to co-promote its shingles vaccine Shingrix in China. Source link

Bristol Myers Squibb, the biopharmaceutical company, will acquire Mirati Therapeutics in a transaction that values the oncology developer at up to $5.8 billion.

Bristol Myers Squibb, the biopharmaceutical company, will acquire Mirati Therapeutics in a transaction that values the oncology developer at up to $5.8 billion. Source link

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion

The deal expands the pharmaceutical company’s portfolio of cancer drugs. Source link